See more : Coca-Cola Bottlers Japan Holdings Inc. (CCOJF) Income Statement Analysis – Financial Results
Complete financial analysis of Ra Medical Systems, Inc. (RMED) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ra Medical Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Karuna Therapeutics, Inc. (KRTX) Income Statement Analysis – Financial Results
- Standard Surfactants Limited (STDSFAC.BO) Income Statement Analysis – Financial Results
- Nightcap Plc (NGHT.L) Income Statement Analysis – Financial Results
- MiX Telematics Limited (MIXT) Income Statement Analysis – Financial Results
- Genetec Technology Berhad (0104.KL) Income Statement Analysis – Financial Results
Ra Medical Systems, Inc. (RMED)
About Ra Medical Systems, Inc.
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 2.23M | 0.00 | 0.00 | 0.00 | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 0.00 | 0.00 |
| Operating Expenses | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 8.77M | 1.57M | 2.37M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -18.20M | -29.27M | -36.06M | -57.73M | -31.16M | -17.54M | -4.10M |
| EBITDA Ratio | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 3.00K | 2.01M | 21.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -26.87M | -27.26M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -191,892.86% | -123,913.64% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Buying Penny Stocks in March 2022? Check These 3 Out
Check these three penny stocks out for your March watchlist The post Buying Penny Stocks in March 2022? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up
Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Are Ra Medical Shares Plunging to 52-Week Low?
Ra Medical Systems Inc RMED has priced an underwritten public offering of 9.535 million units at $0.50 per unit for approximately $12.0 million in gross proceeds. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q3 2021 Results - Earnings Call Transcript
Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q3 2021 Results - Earnings Call Transcript
Ra Medical Systems to Report Third Quarter 2021 Financial Results on November 15, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report third quarter 2021 financial results after market close on Monday, November 15. Ra Medical management will hold an investment community conference call that day at 1:30...
Ra Medical Systems to Report Third Quarter 2021 Financial Results on November 15, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report third quarter 2021 financial results after market close on Monday, November 15. Ra Medical management will hold an investment community conference call that day at 1:30...
Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q2 2021 Results - Earnings Call Transcript
Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q2 2021 Results - Earnings Call Transcript
Ra Medical Systems to Report Second Quarter 2021 Financial Results on August 16, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report second quarter 2021 financial results after market close on Monday, August 16, 2021. Ra Medical management will hold an investment community conference call that day at...
Ra Medical Systems to Report Second Quarter 2021 Financial Results on August 16, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report second quarter 2021 financial results after market close on Monday, August 16, 2021. Ra Medical management will hold an investment community conference call that day at...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Ra Medical Systems, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, June 14, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Ra Medical Systems,...
Source: https://incomestatements.info
Category: Stock Reports